Last Updated: November 16, 2026

Details for Patent: 9,486,458

« Back to Dashboard


Summary for Patent: 9,486,458
Title:Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Abstract:The present invention refers to a new enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives starting from the corresponding 17α,21-diesters which comprises an enzymatic alcoholysis reaction. Furthermore, the present invention refers to new crystalline forms of cortexolone-17α-propionate and 9,11-dehydro-cortexolone 17α-butanoate.
Inventor(s):Mauro Ajani, Luigi Moro
Assignee: Cassiopea SpA
Application Number:US14/886,774
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,486,458
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;
Patent landscape, scope, and claims:

# US Patent 9,486,458: Scope, Claim Construction, Exclusivity, and Cortexolone Patent Landscape

US Patent 9,486,458 protects therapeutic use of crystalline form IV of cortexolone-17α-propionate, also known as clascoterone, for acne and specified androgen-sensitive or sebaceous skin disorders. The patent is narrower than a basic compound patent because infringement requires the claimed crystalline polymorph, the claimed therapeutic indication, and administration to a patient. Claims 1-13 and 14-24 create overlapping protection through two alternative structural definitions of form IV: the powder X-ray diffraction pattern shown in Figure 28 and specified XRPD peaks.

The patent is commercially relevant to Winlevi, the 1% clascoterone cream approved by the FDA for topical treatment of acne vulgaris in patients 12 years and older. It is a small-molecule patent, so biosimilar provisions do not apply. Generic entry would proceed through an ANDA, with potential Paragraph IV challenges to listed patents under the Hatch-Waxman Act. [1][2]

What does US Patent 9,486,458 protect?

The patent protects methods of treating four listed conditions with crystalline form IV of cortexolone-17α-propionate:

Protected element Scope under the issued claims
Active ingredient Cortexolone-17α-propionate
Required solid form Crystalline form IV
Diseases Acne, androgenetic alopecia, hirsutism, or seborrhoeic dermatitis
Administration Systemic administration in claim 1; topical administration in dependent claims
Composition claims Water, a physiologically acceptable excipient, and form IV
Specifically named excipients Propylene glycol, cetylic alcohol, glyceryl monostearate, liquid paraffin, or combinations
Dosage forms Tablet, capsule, powder, pellet, suspension, emulsion, cream, gel, ointment, lotion, or paste
Analytical definition DRX pattern shown in Figure 28 or XRPD peaks at approximately 4.8, 12.9, 14.4, 15.8, 16.0, 19.3, and 19.5 degrees 2θ

The claims do not broadly cover every form of cortexolone-17α-propionate. They require form IV. A product containing amorphous cortexolone-17α-propionate, another polymorph, or a solid form that does not meet the claimed analytical characteristics would present a different infringement question.

How are claims 1 through 24 structured?

The claims contain two substantially parallel claim groups.

Claims 1 through 13: Figure 28 form-IV definition

Claim 1 is the primary treatment claim. It requires:

  1. Treatment of acne, androgenetic alopecia, hirsutism, or seborrhoeic dermatitis.
  2. Administration of an effective amount of crystalline form IV.
  3. Identification of form IV by the DRX pattern shown in Figure 28.

Claim 2 narrows claim 1 to topical administration. Claims 3 through 6 select each of the four diseases individually.

Claim 7 covers treatment with a composition containing:

  • water;
  • at least one physiologically acceptable excipient; and
  • crystalline form IV.

Claim 8 requires topical application of that composition. Claims 9 through 12 select the individual diseases. Claim 13 narrows the composition by naming the excipients.

Claims 14 through 24: XRPD-peak definition

Claim 14 independently defines form IV by XRPD peaks at approximately:

  • 4.8 degrees 2θ;
  • 12.9 degrees 2θ;
  • 14.4 degrees 2θ;
  • 15.8 degrees 2θ;
  • 16.0 degrees 2θ;
  • 19.3 degrees 2θ; and
  • 19.5 degrees 2θ.

Claims 15 through 19 narrow the claim to topical use and select the four indications. Claim 20 adds the specified excipient group. Claim 21 adds the listed dosage forms. Claim 23 requires topical application.

Claims 22 and 24 repeat the dosage-form and topical-use limitations in relation to the composition pathway originating in claim 7.

What is the practical scope of the crystalline-form limitation?

The crystalline-form limitation is the central enforcement feature. An accused product must be tested to determine whether its cortexolone-17α-propionate satisfies the claimed form-IV definition.

The patent uses two types of analytical definition:

DRX pattern shown in Figure 28

"DRX" refers to X-ray diffraction, generally powder X-ray diffraction in the context of pharmaceutical solid-form characterization. A Figure 28 limitation may require comparison of the accused material against the disclosed diffraction pattern, including peak positions and potentially relative intensities, depending on the court's construction and the specification.

Specified XRPD peaks

Claim 14 uses a list of approximate 2θ positions. This provides a more text-based infringement test than the Figure 28 limitation. The word "about" introduces tolerance and makes exact numerical matching unnecessary, but the scope will depend on the specification, measurement conditions, instrumental variation, and construction of the claim term.

A generic manufacturer could attempt to avoid literal infringement by using a different polymorph or an amorphous form. That strategy would not eliminate all risk because:

  • the product may still meet the claim if processing converts the active ingredient into form IV;
  • the composition may contain a mixture that includes form IV;
  • an equivalent-form theory could be asserted, although polymorph claims often raise substantial limits under the all-elements rule and prosecution history;
  • manufacturing and storage conditions could affect the solid form present in the finished dosage form.

The analytical record should distinguish the active pharmaceutical ingredient as manufactured, the active ingredient in the finished formulation, and the form present after storage.

Which diseases and products create the highest infringement exposure?

The most commercially important indication is acne. The remaining indications are androgenetic alopecia, hirsutism, and seborrhoeic dermatitis.

Indication Relevance to US 9,486,458 Commercial exposure
Acne FDA-approved indication for Winlevi Highest
Androgenetic alopecia Expressly claimed but not the current Winlevi FDA indication Potential future-label exposure
Hirsutism Expressly claimed Potential development or off-label exposure
Seborrhoeic dermatitis Expressly claimed Potential development or off-label exposure

A topical generic clascoterone cream for acne would face the clearest risk if it contains form IV. A generic applicant could seek approval for the approved acne indication while challenging the patent through Paragraph IV certification. The method claims remain relevant because an ANDA product is intended for administration to patients for the claimed disease.

Under induced-infringement principles, the generic product's proposed label, promotional materials, prescribing information, and formulation specifications would be important. A label limited to an unpatented use may reduce risk in some circumstances, but it would not automatically resolve a polymorph-based claim directed to the approved use.

What formulations are protected by US 9,486,458?

The patent provides overlapping formulation protection rather than a narrowly defined cream-only claim.

Claim 7 requires a composition containing water, an acceptable excipient, and form IV. Claim 13 identifies propylene glycol, cetylic alcohol, glyceryl monostearate, liquid paraffin, and combinations of those materials.

Claims 20 through 24 extend the formulation coverage to multiple dosage forms:

  • tablets;
  • capsules;
  • powders;
  • pellets;
  • suspensions;
  • emulsions;
  • creams;
  • gels;
  • ointments;
  • lotions; and
  • pastes.

The composition claims do not require every listed excipient. Claim 13 requires one or more of the specified excipients, while claim 7 uses the broader category of at least one physiologically acceptable excipient.

For Winlevi, the commercially relevant embodiment is a topical cream containing 1% clascoterone. The issued claims are broader in dosage-form language than the approved product, but they remain limited by form IV and by the four listed dermatological conditions. [1]

When does US Patent 9,486,458 lose exclusivity?

The patent issued on November 8, 2016, as US Patent No. 9,486,458. Its effective expiration date should be determined from the patent's earliest effective nonprovisional priority date, any patent-term adjustment, and any applicable terminal disclaimer. The patent's commercial exclusivity period may also be affected by FDA-listed patent information and regulatory exclusivity.

The relevant exclusivity layers are:

Exclusivity layer Relevance
Patent term Controls enforceable patent rights, subject to statutory adjustments
New chemical entity exclusivity Winlevi received five years of NCE exclusivity from FDA approval in 2020
Paragraph IV timing A first valid ANDA challenge can trigger a 30-month stay under specified conditions
Pediatric exclusivity Applies only if FDA grants the additional six-month period based on completed written-request studies
Orange Book listing Determines which patents an ANDA applicant must address

Winlevi was approved on July 27, 2020. Its five-year NCE exclusivity generally protected the product from ANDA approval until July 2025, subject to statutory exceptions. Patent protection may extend beyond that period. [1][2]

The exact enforceable patent expiration date should be taken from the current USPTO patent record and FDA Orange Book entry rather than inferred solely from the grant date. Patent-term adjustment can change the ordinary twenty-year calculation. [3][4]

What is the Orange Book status of US 9,486,458?

US 9,486,458 is associated with the clascoterone product approved as Winlevi. Orange Book relevance depends on whether the patent is listed against the specific NDA and whether the listed claims are identified as covering the drug substance, drug product, or method of use.

A listed method-of-use patent can require an ANDA applicant to submit a Paragraph III certification, Paragraph IV certification, or a statement that the relevant method is not being pursued, depending on the listed use and the applicant's proposed labeling. The filing strategy is particularly important for clascoterone because US 9,486,458 contains method claims rather than a simple composition-of-matter claim.

The Orange Book should be reviewed for:

  • the patent number associated with NDA 214276;
  • the listed expiration date;
  • any use code;
  • any later-listed formulation or method patents;
  • certifications filed by ANDA applicants; and
  • the date of any Paragraph IV notice.

FDA's Orange Book is the controlling public regulatory source for listed patents and exclusivity information. [2]

Which companies own or commercialize the clascoterone patent estate?

Winlevi was developed and commercialized by Cassiopea, Inc., now part of Cosmo Pharmaceuticals. The product originated from the cortexolone-17α-propionate development program associated with Cassiopea and its predecessor entities.

The estate may include patents covering separate technical layers:

Patent layer Typical subject matter
Solid form Crystalline form IV and XRPD characteristics
Formulation Cream composition, excipients, stability, and delivery
Therapeutic use Acne and other androgen-responsive disorders
Manufacturing Preparation, crystallization, purification, and control of polymorph
Regulatory protection FDA exclusivity and Orange Book-listed rights

US 9,486,458 is most important as a solid-form and treatment-use patent. It does not, on the supplied claims, establish broad ownership of every formulation or every use of clascoterone.

How strong is the patent estate for clascoterone?

The patent has meaningful but targeted strength.

Strengths

The claims combine the active ingredient, a defined polymorph, a disease, and therapeutic administration. This combination can create a practical barrier if the commercial product consistently contains form IV.

The patent also provides two claim-definition routes. A challenger must assess both the Figure 28 DRX limitation and the listed XRPD peaks. The composition claims add risk for formulations containing water and the named excipients.

The claims cover acne, the approved Winlevi indication, while also reaching three additional dermatological conditions. That expands the potential use-code and development relevance.

Limitations

The claims are not composition-of-matter claims to clascoterone itself. They may be vulnerable to a non-infringing solid form, depending on the technical feasibility and regulatory acceptability of using that form.

The disease limitations also narrow the claims. A product directed to a different condition may avoid literal infringement of these claims, although other patents could apply.

The claims require an effective amount and a treatment method. They do not expressly claim every manufacturing step used to produce form IV. Separate process patents would be needed to create a manufacturing-specific barrier.

What generic entry risks exist for Winlevi?

A generic applicant has four principal routes:

  1. Paragraph III certification: accept the listed patent and delay approval until expiration.
  2. Paragraph IV certification: assert that the patent is invalid, unenforceable, or not infringed.
  3. Carve-out strategy: omit a patented method from the proposed labeling where FDA rules permit.
  4. Non-infringing polymorph strategy: develop a different solid form, subject to pharmaceutical development, stability, bioequivalence, and regulatory requirements.

The strongest technical design-around would avoid form IV in the finished drug product. That approach creates development risk because polymorph selection can affect solubility, particle size, suspension behavior, release, stability, and topical delivery.

A Paragraph IV challenge would likely focus on:

  • anticipation or obviousness of form IV;
  • whether the XRPD peaks adequately identify a distinct polymorph;
  • written-description and enablement issues;
  • indefiniteness of "about" and the Figure 28 characterization;
  • infringement by the proposed generic's active ingredient;
  • prosecution-history limitations; and
  • the scope of any Orange Book-listed use code.

What patent litigation and settlements affect clascoterone?

The claims supplied do not identify a litigation judgment, settlement, or license. The relevant public records for transaction and litigation review are USPTO Patent Center, PACER, FDA Orange Book records, and SEC filings of the patent owner or licensee.

A litigation assessment should separate:

  • patent validity disputes;
  • ANDA infringement actions;
  • inter partes review or post-grant proceedings;
  • ownership and chain-of-title disputes;
  • licensing agreements;
  • co-development arrangements; and
  • settlement agreements controlling generic launch timing.

No biosimilar litigation framework applies because clascoterone is a chemically synthesized small molecule, not a biologic under the Public Health Service Act.

How does US 9,486,458 compare with a basic compound patent?

Issue US 9,486,458 Compound-of-matter patent
Protected subject Form IV plus treatment method Chemical molecule itself
Technical limitation XRPD/DRX-defined polymorph Chemical structure
Design-around potential Higher Usually lower
Relevance to finished product Direct if product contains form IV Direct regardless of polymorph
Formulation coverage Present through method claims Not necessarily present
Manufacturing coverage Limited on supplied claims Not necessarily present
Generic challenge focus Polymorph validity and infringement Novelty, obviousness, structure and utility

The patent is commercially significant because a polymorph can be embedded in the approved product and may be difficult to replace without reformulation. Its legal strength is narrower than a foundational compound patent, but its practical value can remain high when the marketed product depends on the claimed crystalline form.

Key Takeaways

  • US 9,486,458 covers treatment of acne, androgenetic alopecia, hirsutism, and seborrhoeic dermatitis with crystalline form IV of cortexolone-17α-propionate.
  • The patent uses both a Figure 28 DRX definition and a seven-peak XRPD definition.
  • Claims 7 through 13 and 20 through 24 add water, excipients, dosage forms, and topical administration.
  • Winlevi's FDA-approved acne cream is the principal commercial product implicated by the patent.
  • Generic entry would use the ANDA pathway and could involve Paragraph IV certification.
  • A biosimilar pathway does not apply.
  • The principal technical design-around is a different polymorph or amorphous form, but that strategy carries formulation and regulatory risk.
  • Patent-term and Orange Book conclusions should be based on the current USPTO and FDA records, including any patent-term adjustment and listed use code.

FAQs About US Patent 9,486,458 and Clascoterone

Does US 9,486,458 cover clascoterone in every physical form?

No. The supplied claims require crystalline form IV, identified by a DRX pattern or specified XRPD peaks.

Can a generic clascoterone product avoid the patent by using a different polymorph?

Potentially. A different polymorph could avoid literal infringement if it does not satisfy the form-IV limitations, but the alternative must still meet pharmaceutical quality, stability, topical-performance, and FDA requirements.

Does the patent cover oral clascoterone?

The independent claims are not limited to topical administration, but the dependent claims emphasize topical use. The disease, form-IV, composition, and effective-amount limitations still apply.

Are androgenetic alopecia and hirsutism FDA-approved Winlevi indications?

No. The patent claims those conditions, but FDA approval of Winlevi is for topical treatment of acne vulgaris in patients 12 years and older. [1]

Is a license required to sell a clascoterone product in the United States?

A license may be commercially necessary if the product practices an unexpired, enforceable patent or other licensed intellectual-property right. The patent alone does not establish the terms of any private license or settlement.

References

  1. U.S. Food and Drug Administration. (2020, July 27). FDA approves new treatment for acne. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-acne
  2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
  3. U.S. Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/
  4. U.S. Patent and Trademark Office. (n.d.). Patent term adjustment. https://www.uspto.gov/patents/laws/patent-term-adjustment-patent-term-extension/patent-term-adjustment p

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 9,486,458

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sun Pharm WINLEVI clascoterone CREAM;TOPICAL 213433-001 Aug 26, 2020 RX Yes Yes ⤷  Start Trial ⤷  Start Trial METHOD OF TREATING ACNE VULGARIS WITH TOPICALLY APPLIED CORTEXOLONE 17A-PROPIONATE ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,486,458

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2503005 ⤷  Start Trial C20250037 Finland ⤷  Start Trial
European Patent Office 2503005 ⤷  Start Trial CA 2025 00047 Denmark ⤷  Start Trial
European Patent Office 2503005 ⤷  Start Trial 301358 Netherlands ⤷  Start Trial
European Patent Office 2503005 ⤷  Start Trial 2025C/551 Belgium ⤷  Start Trial
European Patent Office 2503005 ⤷  Start Trial CR 2025 00047 Denmark ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.